Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Limited has submitted a regulatory application to the British Standards Institution for approval to distribute its nerve repair product, Remplir™, in the EU and UK markets, which represent a combined market size of US$750 million. The company expects to receive the necessary certifications by the third quarter of 2026, enabling it to expand its global market presence. The application is supported by strong clinical evidence, including an 81.1% treatment success rate from recent studies, positioning Remplir™ as a key player in nerve repair surgery. Orthocell’s strategy includes forming a panel of key opinion leaders and utilizing in-country distributors to drive market adoption, supported by a robust financial position with approximately $50 million in cash.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company that specializes in developing and commercializing products for nerve repair. The company focuses on the global nerve repair market, with its primary product, Remplir™, targeting significant markets such as the EU, UK, and others worldwide.
Average Trading Volume: 829,623
Technical Sentiment Signal: Buy
Current Market Cap: A$276.5M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.